| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,290 | 0,336 | 28.02. | |
| 0,360 | 0,430 | 09.02. |
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 12.02. | Anebulo Pharmaceuticals GAAP EPS of -$0.05 | 2 | Seeking Alpha | ||
| 12.02. | Anebulo Pharmaceuticals, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 06.02. | Anebulo Pharmaceuticals: Aktie bricht nach Ankündigung des NASDAQ-Delistings ein | 1 | Investing.com Deutsch | ||
| 06.02. | Anebulo Pharmaceuticals plant Delisting von der Nasdaq und Deregistrierung bei der SEC | 1 | Investing.com Deutsch | ||
| 06.02. | Anebulo Pharmaceuticals, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 06.02. | Anebulo Pharmaceuticals to delist from Nasdaq, deregister with SEC | 1 | Investing.com | ||
| 06.02. | Anebulo Pharmaceuticals, Inc. Announces Intention to Voluntarily Delist from Nasdaq and Deregister with SEC | 150 | Business Wire | AUSTIN, Texas--(BUSINESS WIRE)--Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage pharmaceutical company developing novel solutions for people suffering from acute cannabis-induced toxic... ► Artikel lesen | |
| ANEBULO PHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
| 27.01. | Anebulo Pharmaceuticals, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 27.01. | Anebulo schließt stark überzeichnetes Aktienrückkaufangebot ab | 7 | Investing.com Deutsch | ||
| 27.01. | Anebulo completes oversubscribed share repurchase tender offer | 2 | Investing.com | ||
| 22.12.25 | Anebulo Pharmaceuticals verwirft Reverse Split - Aktie stürzt ab | 7 | Investing.com Deutsch | ||
| 22.12.25 | Anebulo shifts from reverse stock split to tender offer in go-private plan | 10 | Investing.com | ||
| 22.12.25 | Anebulo Pharmaceuticals, Inc. Announces Its Intent to Commence a Self Tender Offer | 130 | Business Wire | AUSTIN, Texas--(BUSINESS WIRE)--Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage pharmaceutical company developing novel solutions for people suffering from acute cannabis-induced toxic... ► Artikel lesen | |
| 22.12.25 | Anebulo Pharmaceuticals, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 13.11.25 | Anebulo Pharmaceuticals, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 30.09.25 | Anebulo Pharmaceuticals, Inc. Loss At -$2.14 Mln In Q4 | 3 | RTTNews | ||
| 29.09.25 | Anebulo Pharmaceuticals, Inc. - 10-K, Annual Report | 2 | SEC Filings | ||
| 29.09.25 | Anebulo Pharmaceuticals, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 25.09.25 | Anebulo begins phase 1 trial of IV cannabis toxicity treatment | 2 | Investing.com | ||
| 12.09.25 | Anebulo Pharmaceuticals, Inc. - 8-K, Current Report | 1 | SEC Filings |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 93,10 | -0,21 % | BioNTech, Valneva oder BB Biotech: Warum es HIER in Kürze knallt! | Die Biotechbranche steht zu Beginn des Jahres 2026 erneut im Spannungsfeld zwischen wissenschaftlicher Innovation und wachsender Skepsis der Kapitalmärkte. Nach Jahren extremer Kursbewegungen prüfen... ► Artikel lesen | |
| EVOTEC | 5,880 | +0,38 % | Evotec: Das Biotech-Drama geht in die nächste Runde | Die Aktie des Hamburger Wirkstoffforschers Evotec versucht erneut den Befreiungsschlag, doch das Misstrauen am Markt ist greifbar. Nach einer beispiellosen Serie von Rückschlägen - von Management-Skandalen... ► Artikel lesen | |
| MODERNA | 45,160 | -0,41 % | Aufgrund von angeblichen Patentverletzungen zieht BioNTech gegen Moderna vor Gericht | Die Hersteller von Corona-Impfstoffen haben sich schon seit Jahren in den Haaren. Immer wieder gibt es Vorwürfe über Patentverletzungen. So auch in einem aktuellen Fall, bei dem BioNTech gegen den US-Hersteller... ► Artikel lesen | |
| AMGEN | 328,50 | -0,02 % | Is Amgen Stock Outperforming the Dow? | ||
| STRYKER | 327,20 | -0,24 % | Think Surgical announces first TMINI robot cases with Stryker knee implant | ||
| BIOGEN | 162,45 | +0,06 % | WONBIOGEN Co., Ltd: Won BioGen Accelerates Global Market Expansion with Advanced Moist Wound Care Technology | SEOUL, South Korea, Feb. 24, 2026 /PRNewswire/ -- Medical device manufacturer Won BioGen (CEO Kim Won-il) is accelerating its global market expansion based on its advanced moist wound care... ► Artikel lesen | |
| CRISPR THERAPEUTICS | 50,50 | -0,98 % | Crispr Therapeutics gains amid takeover speculation | ||
| 4SC | 0,100 | -23,37 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 16.12.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 16.12.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 16.12.2025ISIN NameDE000A3E5C40 4SC... ► Artikel lesen | |
| INOVIO PHARMACEUTICALS | 1,500 | -2,60 % | Is Inovio Pharmaceuticals Stock Going to $0? | ||
| MAINZ BIOMED | 0,748 | +2,78 % | Mainz BioMed NV: Mainz Biomed to Present at the Pancreatic Cancer Session at Digestive Disease Week, Demonstrating Effectiveness of mRNA Biomarkers in Blood Samples | ||
| TREVENA | 4,000 | +1.983 % | TREVENA INC - 8-K, Current Report | ||
| ABIVAX | 101,80 | -0,97 % | 2 Reasons Abivax Stock Could 10X by 2036 | ||
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,438 | +0,86 % | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. - S-8, Securities to be offered to employees in employee benefit plans | ||
| HALOZYME THERAPEUTICS | 59,08 | +0,37 % | Halozyme Therapeutics, Inc.: Halozyme Reports Full Year 2025 Record Revenue Of $1.4 Billion And Reiterates Strong 2026 Financial Guidance | Full Year 2025 Total Revenue Increased 38% YOY to Record $1.397 billionFull Year 2025 Royalty Revenue Increased 52% YOY to Record $868 million
Completed Acquisitions... ► Artikel lesen | |
| EXACT SCIENCES | 87,11 | -0,17 % | Exact Sciences (EXAS) Merger with Abbott Moving Forward After Shareholder Approval |